北京若生智能科技有限公司
Drug Database
DI

diphtheria+tetanus+bordetella pertussis vaccine (DPT Kovax)

✓ Approved

Korea Vaccine Company · 细胞治疗 · 细胞治疗

什么是 diphtheria+tetanus+bordetella pertussis vaccine？

diphtheria+tetanus+bordetella pertussis vaccine 是一种细胞治疗，由Korea Vaccine Company研发。该药已获批，用于治疗相关适应症，给药途径：Injectable (Others)、Intramuscular (IM) Injection、Subcutaneous Injection。

药物档案

商品名DPT Kovax
公司Korea Vaccine Company
药物类别细胞治疗, 疫苗
给药途径Injectable (Others), Intramuscular (IM) Injection, Subcutaneous Injection
状态Approved
来源： ClinicalTrials.gov, Korea Vaccine Company

治疗适应症

diphtheria+tetanus+bordetella pertussis vaccine 针对 3 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Infections and infestationsDiphtheria✓ Approved
Infections and infestationsPertussis✓ Approved
Infections and infestationsTetanus✓ Approved

相关研究文献

PubMedBMC infectious diseases2026-10-27

Epidemiology, vaccine effectiveness, and risk factors of pertussis in Xinjiang children: a retrospective study.

Ru Liang L, Zhu Hongtao H, Ma Xiangping X, Abuduhaer Abulaiti A et al.

Despite the high global vaccination coverage, the incidence of pertussis is rising in many countries. The epidemiological data on pertussis in children in the Xinjiang region are limited. This study aims to investigate the epidemiological characteristics of pertussis in this region, the protective effectiveness of vaccines, and the independent risk factors associated with the disease. A retrospective study was conducted among 2,250 children with suspected pertussis who presented to the Pediatric Center of the First Affiliated Hospital of Xinjiang Medical University from March 2024 to June 2025. Children aged ≤ 18 years who met the suspected case criteria of the Chinese Guidelines for Diagnosis, Treatment and Prevention of Pertussis (2024 edition) and underwent nasopharyngeal PCR testing were included. Demographic, clinical, vaccination, and laboratory data were collected. Bordetella pertussis DNA was detected using a fluorescence probe-based PCR method. The χ² test was used to compare the differences between groups, and univariate and multivariate logistic regression analyses were used to identify independent risk factors. The overall positivity rate of pertussis was 9.3%. The positivity rate was the highest during the months of July to September. Moreover, the positivity rate was the highest in infants younger than 6 months (17.4% in 0-2 months and 16.2% in 3-5 months). The vaccination coverage was 90.3%; however, 82.9% of the positive cases had been vaccinated. Among children aged ≥ 3 months (eligible for vaccination), vaccine effectiveness (VE) against laboratory-confirmed pertussis was 47.1% (95% CI: 9.4-69.1%) for ≥ 1 dose versus unvaccinated. Multivariate analysis showed that age, season, history of cough contact, and laboratory markers (lymphocytosis) were independent predictors of pertussis positivity. In the age-restricted multivariable analysis (≥ 3 months, n = 1,741 complete cases), summer was the strongest risk factor (adjusted odds ratio [aOR] = 5.25, 95% confidence intervals [CI]: 3.27-8.45). History of cough contact (aOR = 2.54) and lymphocytosis > 50% (aOR = 1.56) were significant risk factors. The age group of 1-2 years showed the strongest protective effect (aOR = 0.16, p = 0.006), reflecting a U-shaped age-risk curve. In this single-center retrospective study of suspected pertussis cases in Xinjiang, children who tested positive were more likely to present in summer, have paroxysmal cough, and report a history of cough contact. Despite 90.3% vaccination coverage, the overall positivity rate was 9.3%, with a U-shaped age distribution peaking in infants aged 0-5 months and children ≥ 6 years. These findings highlight the potential value of maternal immunization strategies and timely booster vaccination, though multi-center prospective studies are needed to confirm these observations. Not applicable.

PMID 42934535
阅读全文 →
PubMedFrontiers in public health2026-10-27

An age-structured mathematical model of tetanus epidemiology, immunity, and vaccination across the life course.

Hounsell Rachel A RA, Norman Jared J, Silal Sheetal P SP

Tetanus remains a significant public health concern despite substantial reductions in incidence and mortality following the widespread introduction of tetanus-toxoid-containing vaccines (TTCVs). Because immunity is acquired only through vaccination and wanes over time, the World Health Organization recommends three booster doses throughout childhood and adolescence in addition to the three-dose infant primary series. However, few mathematical models explicitly represent the cumulative, dose-dependent nature of tetanus immunity needed to evaluate alternative vaccination strategies. We developed a novel age-structured model of tetanus epidemiology, immunity, and vaccination to address this gap. We developed a deterministic compartmental model stratified by age, vaccination history, and immunity status. The model incorporates environmental exposure, neonatal and non-neonatal tetanus, routine infant vaccination, booster doses, maternal immunization, and waning immunity. Unlike previous tetanus models, each TTCV dose is represented explicitly, allowing protection, waning, and booster responses to vary according to vaccination history. Model parameters were informed by published literature and expert consultation. Sensitivity analyses were conducted using Latin hypercube sampling and partial rank correlation coefficients, and model outputs were compared with published seroprevalence studies. The model reproduced expected patterns of vaccine-derived immunity and waning described in the literature and generated population protection estimates consistent with seroprevalence data from settings with different vaccination schedules. Sensitivity analyses identified the duration of vaccine-derived protection as a primary source of uncertainty, with vaccine effectiveness also substantially influencing population immunity. The framework successfully captured heterogeneous immunity profiles by age and vaccination history and the cumulative effects of primary series, booster doses, and maternal vaccination. This model provides a novel framework for representing cumulative TTCV-derived immunity across the life course. By explicitly tracking dose-specific protection and waning, it enables the evaluation of booster-dose strategies and maternal immunization programs and provides a platform for informing evidence-based tetanus vaccination policy.

PMID 42935852
阅读全文 →
PubMedMicrobiology spectrum2026-10-27

Seasonal changes of respiratory infections in Northern Finland 2019-2024: evaluation of different diagnostic tests in rapidly changing epidemiological environment.

Juusola Terhi T, Aho-Laukkanen Elina E, Jokelainen Jari J, Junttila Ilkka S IS et al.

In primary health care, respiratory tract infections (RTIs) are one of the major causes of seeking medical attention. Diagnostic RTI laboratory tests provide information for both treating an individual patient as well as more generally epidemiological disease distribution of a given infection. In the case of SARS-CoV-2 pandemic, a diagnostic qPCR assay was rapidly developed in 2020, and the virus-specific test was subsequently incorporated into multiplex PCR tests that also detect other common seasonally occurring viruses, including influenza A and B, and RS-virus. We provide here the data on epidemiological distribution of 23 microbes between 2019 and 2024 in Northern Finland. While coronavirus was the most prominent detected microbe, adenovirus, RS-virus, influenzas, Mycoplasma pneumoniae, Chlamydia pneumoniae, and Bordetella pertussis/parapertussis were also commonly detected microbes. The incorporation of multiplex PCR into diagnostics of RTI, particularly in primary health care, will provide more epidemiological data; however, the cost-effectiveness of laboratory tests compared with data availability remains to be clarified. Respiratory tract infections (RTIs) are one of the major causes of health care visits. The role of laboratory diagnostics is important, as RTIs have numerous etiological pathogens, and the clinical symptoms may be similar. The distinction between viral and bacterial infections is important to avoid unnecessary antibiotic treatments. The data from RTI testing provide a wide perspective on the epidemiological situation before, during, and after the COVID-19 pandemic and provides insights into the differences in detection rates between age groups.

PMID 42937324
阅读全文 →
PubMedLife (Basel, Switzerland)2026-10-27

Generalized Tetanus in a Four-Month-Old Labrador Retriever: Complete Recovery and One-Year Follow-Up in a Rare Canine Case.

Fernoagă Cristina C, Turbatu Raluca Mihaela RM, Neagu Alexandru Gabriel AG, Pavel Ruxandra R et al.

Tetanus is an infrequent, potentially fatal neurological disease in dogs, caused by tetanospasmin, the neurotoxin of Clostridium tetani, which reaches the central nervous system by retrograde axonal transport and blocks the release of the inhibitory neurotransmitters glycine and γ-aminobutyric acid. Dogs are comparatively resistant to the toxin, and canine reports remain scarce. This report describes generalized tetanus in a four-month-old, 13 kg male Labrador Retriever presented with an axillary wound sustained approximately one month earlier and neurological signs progressing over approximately seven days, from gait disturbance to generalized whole-body rigidity. On examination the dog showed trismus, risus sardonicus, cervical hyperextension, opisthotonos, third-eyelid protrusion, a sawhorse stance, hyperthermia and intermittent respiratory distress. The diagnosis was established clinically, following a structured neurological work-up and exclusion of the principal differentials, as confirmatory assays were unavailable. Total serum calcium was within the reference interval; serum creatine kinase was elevated; and venous blood-gas analysis indicated a mild, compensated metabolic acidosis. Management comprised metronidazole and clindamycin, equine tetanus antitoxin, diazepam, meloxicam and intensive nursing care in a low-stimulation environment. The dog improved from the first day of hospitalization and recovered without residual deficits, with no recurrence over one year of follow-up. The favorable outcome, in a young canine patient for which the literature would predict a guarded prognosis, is consistent with the absence of clinically detectable autonomic and cardiorespiratory dysfunction and with meticulous supportive care.

PMID 42942178
阅读全文 →
PubMedBiomedicines2026-10-27

Bivalent CD47 Immunotoxin for Targeted Therapy of Lung Cancer.

Ma Jihong J, Menon Dinoop Ravindran DR, Wang Zhaohui Z, Mintzlaff Danielle D et al.

Background/Objectives: Lung cancer is the leading cause of cancer-related death in the world, with ~2.5 million people diagnosed and ~1.5 million deaths each year. While the last two decades have yielded substantial progress, with systemic targeted and immune therapies improving treatment responses in subgroups of patients with advanced and refractory lung cancer, there is still a dire unmet clinical need to develop more effective therapies with durable responses. CD47 receptors are overexpressed on the surface of a variety of malignant tumor cells, including lung cancer. Although there has been increasing interest in developing targeting antibodies against CD47 for immunotherapy, they failed clinical trials due to their dose-limiting toxicities, primarily hematopoietic toxicity. Methods: Recently, using a unique diphtheria toxin-resistant Pichia pastoris yeast expression system, we developed a diphtheria toxin-based bivalent CD47 immunotoxin (bi-CD47-IT) for targeted therapy of CD47+ cancers. In this study, we extended application of the targeted therapy bi-CD47-IT to a solid tumor, specifically lung cancer. Results: Bi-CD47-IT demonstrated compelling preclinical efficacy in multiple non-small cell lung cancer (NSCLC) cell line-derived xenograft (CDX) and patient-derived xenograft (PDX) mouse models, including subcutaneous, orthotopic, metastatic, and humanized models. Conclusions: This study demonstrates the remarkable preclinical activity of bi-CD47-IT against various lung cancer models, making bi-CD47-IT a novel and promising therapeutic approach for NSCLC.

PMID 42939986
阅读全文 →
PubMedAnimals : an open access journal from MDPI2026-10-27

An mRNA-LNP Vaccine Encoding the Erns-E1-E2 Polyprotein Confers Complete Protection Against Bovine Viral Diarrhea Virus in Mice.

Yue Zongzhe Z, Li Yanmin Y, Yang Hongjun H, Bian Shiao S et al.

Bovine viral diarrhea virus (BVDV) remains a major barrier to sustainable livestock development. Conventional BVDV vaccines are limited by inherent drawbacks such as potential virulence reversion and insufficient protective efficacy, which severely hamper global BVDV eradication efforts. mRNA vaccine technology, characterized by high expression efficiency, a favorable safety profile, and scalable manufacturing, offers a promising platform for next-generation BVDV vaccine development. In this study, we developed an mRNA-LNP vaccine candidate (Erns/E1/E2 vaccine) encoding the full-length structural glycoproteins Erns, E1 and E2, and systematically evaluated its immunogenicity and protective efficacy in BALB/c mice. The E2 extracellular domain-human IgG1 Fc fusion mRNA vaccine (E2/IgG1 vaccine) and a commercial inactivated BVDV vaccine served as controls. Our results demonstrated that the Erns/E1/E2 vaccine elicited significantly higher neutralizing antibody titers (log10NT50 = 2.50 ± 0.082) and lymphocyte proliferation responses (stimulation index = 6.927 ± 0.145) than both control vaccines at 28 days post-primary vaccination (two weeks post-booster). Notably, no viral RNA was detected in any tissue or blood samples from Erns/E1/E2-immunized mice at any time point following BVDV challenge, indicating complete immune protection against viral infection, whereas viral loads were consistently detected in multiple tissues of both control groups. These findings establish the Erns/E1/E2 vaccine as a highly promising BVDV vaccine candidate and provide critical experimental support for advancing mRNA-based BVDV vaccine development.

PMID 42939244
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多diphtheria+tetanus+bordetella pertussis vaccine